VA Respiratory C&P Exam and DBQ Guide: Spirometry, Inhalers, and Evidence

VA compensation examiners use the standardized Respiratory Conditions Disability Benefits Questionnaire (DBQ) to gather objective clinical findings for lung conditions such as asthma, COPD, chronic bronchitis, and interstitial lung diseases. The form requires the examiner to document specific diagnostic confirmations, symptom frequency, physical chest examination findings, spirometric testing values, and functional occupational impact.

When pulmonary function tests are performed during a C&P exam, examiners generally conduct pre- and post-bronchodilator spirometry to record FEV-1, FVC, and FEV-1/FVC values. Under 38 CFR 4.96(d), post-bronchodilator studies are generally used for rating, but they are not required if pre-bronchodilator results are normal or if testing is clinically contraindicated. Crucially, if post-bronchodilator results are worse than pre-bronchodilator values, the pre-bronchodilator figures are used. In addition, PFTs are not required at all if the veteran has documented outpatient oxygen therapy, cor pulmonale, or acute respiratory failure.

Because asthma under DC 6602 can be rated based entirely on prescribed medications rather than spirometry alone, examiners must meticulously record the veteran's medication history. The DBQ prompts the clinician to document daily maintenance inhalers, daily anti-inflammatory medications, and the exact count of systemic oral or injected corticosteroid bursts administered over the preceding 12 months.

Beyond numerical PFT values, the DBQ requires the examiner to assess how chronic cough, dyspnea on exertion, wheezing, and reduced lung capacity diminish occupational efficiency. Claimants should explain specific functional limitations, such as difficulty walking up stairs, lifting heavy objects, or performing work in environments containing dust, chemical fumes, or extreme temperature swings.

Before attending a respiratory C&P exam, veterans should compile complete spirometry tracings and flow-volume loops from private pulmonologists, 12-month pharmacy prescription refill records proving consistent inhaler use, emergency room discharge summaries for acute asthma exacerbations, and personal statements describing flare-up frequency.